MEDEXUS PHARMACEUTICALS INC.
Ownership & governance
Executives 3Directors 7Avg age 62Avg tenure 6.4y
KD
Kenneth d’Entremont
Chief Executive Officer
Since 2018-12-16Profile →
+9
Executives3
Board of directors7
MM
Michael Mueller→
Chairman
Age 66Since 2023-04-10
BG
Benoit Gravel→
Director/Board Member
—Since 2017-09-21
KD
Kenneth d’Entremont→
Director/Board Member
—Since 2018-10-15
SN
Stephen Nelson→
Director/Board Member
—Since 2018-10-15
MT
Menassie Taddese→
Director/Board Member
—Since 2023-02-05
HG
Harmony Garges→
Director/Board Member
—Since 2023-02-05
NP
Nancy Phelan→
Director/Board Member
Age 57Since 2023-09-20
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Kenneth d’Entremont | 4.659 % | 1,504,807 |
| Stephen Nelson | 2.07 % | 668,588 |
| Arrow Capital Management, Inc. | 1.753 % | 566,300 |
| Michael Mueller | 0.3469 % | 112,055 |
| Brendon Buschman | 0.2772 % | 89,538 |
Catalog · 2026-07-09
Registry officers10
| Name | Role | Since | Shares |
|---|---|---|---|
| Brendon Buschman | Director of Finance/CFO | 2019-05-31 | - |
| Kenneth d’Entremont | Chief Executive Officer | 2018-12-16 | - |
| Michael Mueller | Chairman | 2023-04-10 | - |
| Richard Labelle | Chief Operating Officer | 2014-02-17 | - |
| Benoit Gravel | Director/Board Member | 2017-09-21 | - |
| Harmony Garges | Director/Board Member | 2023-02-05 | - |
| Kenneth d’Entremont | Director/Board Member | 2018-10-15 | - |
| Menassie Taddese | Director/Board Member | 2023-02-05 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus noneMean target 7.25Range 6–9Analysts 5
6Mean 7.259
- Buy 6
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.